Table 3. National prevalence and burden of MetS in Iranian adults aged ≥25 years based on various MetS definitions (for all ages).
| Sex | Area | ATP III | IDF | AHA/NHLBI | JIS | Regional IDF | Regional JIS | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prevalence (%, 95% CI) | Burden* (%, 95% CI) | Prevalence (%, 95% CI) | Burden* (%, 95% CI) | Prevalence (%, 95% CI) | Burden* (%, 95% CI) | Prevalence (%, 95% CI) | Burden* (%, 95% CI) | Prevalence (%, 95% CI) | Burden* (%, 95% CI) | Prevalence (%, 95% CI) | Burden* (%, 95% CI) | ||
| Both | Both | 38.3 (37.4–39.1) | 18.7 (18.3–19.1) | 43.5 (42.7–44.4) | 21.3 (20.9–21.7) | 40.9 (40.1–41.8) | 20.0 (19.6–20.4) | 47.6 (46.8–48.5) | 23.3 (22.9–23.7) | 32.0 (31.2–32.9) | 15.7 (15.3–16.1) | 40.8 (40.0–41.7) | 20.0 (19.5–20.4) |
| Rural | 33.5 (32.2–34.8) | 3.9 (3.8–4.0) | 38.1 (36.8–39.4) | 4.5 (4.3–4.6) | 35.6 (34.3–36.9) | 4.2 (4.0–4.3) | 41.7 (40.3–43.0) | 4.9 (4.7–5.0) | 27.4 (26.2–28.6) | 3.2 (3.1–3.3) | 35.7 (34.4–37.0) | 4.2 (4.0–4.3) | |
| Urban | 40.3 (39.3–41.4) | 14.8 (14.5–15.1) | 45.8 (44.7–46.9) | 16.8 (16.5–17.1) | 43.1 (42.1–44.2) | 15.8 (15.6–16.1) | 50.2 (49.1–51.3) | 18.4 (18.1–18.7) | 34.0 (33.0–35.0) | 12.5 (12.2–12.7) | 43.0 (41.9–44.1) | 15.8 (15.5–16.1) | |
| Female | Both | 43.8 (42.6–45.0) | 10.8 (10.6–11.0) | 50.6 (49.4–51.8) | 12.5 (12.3–12.7) | 46.9 (45.7–48.1) | 11.5 (11.3–11.7) | 52.1 (50.9–53.3) | 12.7 (12.5–12.9) | 31.2 (30.1–32.3) | 7.5 (7.4–7.7) | 40.3† (39.1–41.4) | 9.8 (9.6–10.0) |
| Rural | 41.6 (39.8–43.5) | 2.5 (2.4–2.5) | 47.5 (45.6–49.3) | 2.8 (2.7–2.9) | 44.3 (42.5–46.2) | 2.6 (2.6–2.7) | 49.0 (47.2–50.9) | 2.9 (2.8–2.9) | 29.2 (27.5–30.9) | 1.7 (1.6–1.8) | 38.6 (36.8–40.4) | 2.2 (2.2–2.3) | |
| Urban | 44.7 (43.2–46.2) | 8.3 (8.2–8.4) | 51.9 (50.4–53.4) | 9.7 (9.5–9.8) | 47.9 (46.4–49.4) | 8.9 (8.8–9.0) | 53.3 (51.8–54.8) | 9.9 (9.7–10.0) | 32.0 (30.6–33.4) | 5.8 (5.7–6.0) | 41.0 (39.5–42.4) | 7.5 (7.4–7.6) | |
| Male | Both | 31.8 (30.6–33.0) | 7.9 (7.7–8.2) | 35.2 (34.0–36.4) | 8.8 (8.6–9.0) | 33.9 (32.7–35.1) | 8.5 (8.2–8.7) | 42.4 (41.2–43.7) | 10.5 (10.3–10.8) | 33.1 (31.9–34.3) | 8.1 (7.9–8.3) | 41.5† (40.2–42.7) | 10.2 (10.0–10.4) |
| Rural | 24.3 (22.6–26.0) | 1.5 (1.4–1.5) | 27.4 (25.7–29.1) | 1.6 (1.6–1.7) | 25.8 (24.1–27.5) | 1.5 (1.5–1.6) | 33.3 (31.5–35.2) | 2.0 (1.9–2.1) | 25.4 (23.7–27.1) | 1.5 (1.4–1.6) | 32.4 (30.6–34.2) | 1.9 (1.8–2.0) | |
| Urban | 35.1 (33.6–36.6) | 6.5 (6.3–6.6) | 38.6 (37.0–40.2) | 7.2 (7.0–7.3) | 37.4 (35.9–39.0) | 6.9 (6.8–7.1) | 46.4 (44.8–48.0) | 8.6 (8.4–8.7) | 36.4 (34.9–38.0) | 6.6 (6.5–6.8) | 45.4 (43.8–47.0) | 8.3 (8.1–8.4) | |
ATP III: National Cholesterol Education Program Adult Treatment Panel III; IDF: International Diabetes Federation; AHA/NHLBI: American Heart Association/National Heart, Lung, and Blood Institute; JIS: Joint Interim Statement; MetS: Metabolic Syndrome; 95% CI: 95% Confidence Interval.
-Data are presented as point estimates and 95% CI.
*Rounded to the nearest million.
†P value was statistically non-significant (P = 0.173) using Chi-Square analysis, but other P-values were statistically significant (P≤0.05).